A new trading day began on Friday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price down -0.27% from the previous day of trading, before settling in for the closing price of $11.06. VERV’s price has ranged from $2.86 to $11.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -42.43% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -4.53%. With a float of $65.76 million, this company’s outstanding shares have now reached $88.80 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 36.09%, operating margin of -349.68%, and the pretax margin is -303.09%.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 73.90%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -4.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.31% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Let’s dig in a bit further. During the last 5-days, its volume was 2.48 million. That was inferior than the volume of 3.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.60%.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 95.67%, which indicates a significant increase from 3.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.12 in the past 14 days, which was lower than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.09, while its 200-day Moving Average is $6.18. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $11.07. Second resistance stands at $11.12. The third major resistance level sits at $11.14. If the price goes on to break the first support level at $11.00, it is likely to go to the next support level at $10.98. The third support level lies at $10.93 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 983.25 million, the company has a total of 89,143K Shares Outstanding. Currently, annual sales are 32,330 K while annual income is -198,710 K. The company’s previous quarter sales were 32,980 K while its latest quarter income was -31,030 K.
